Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435928 · ClinicalTrials.gov registry record · Phase 3
PEARL Schizophrenia Maintenance
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
NCT01435928: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT01435928 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 676 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01435928, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
Study Summary
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
Primary Outcome
The Kaplan-Meier method is used for the estimation.
Interventions
- DRUG Matching Placebo
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT01435928 record still lists
NCT01435928 is an interventional study that assigns participants to a tested intervention. The registered 676 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01435928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01435928 about?
NCT01435928 is a clinical study titled "PEARL Schizophrenia Maintenance". Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
What is the current status of trial NCT01435928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2011-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01435928?
The interventions under investigation include: Matching Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01435928?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01435928's enrollment target sits among peer trials
676 537th of 2000 higher than 1,463 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07227337 · 676 participants · NA
Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia